Emerging therapies for herpes viral infections (types 1 – 8)

Bibliography

• NAHMIAS AJ,LEE FK, BECKMAN-NAHMIAS S: Sero-epidemiological and sociological patterns of herpes simplex virus infection in the world. Scand J. Infect. Dis. (1990) 69:19–36.
   Google Scholar
• JOHNSON LS, NAHMIAS AJ, MAGDER RE et al.: A seroepidemiologic survey of the prevalence of herpes simplex virus Type 2 infection in the United States. N. Engl. J. Med. (1989) 321:7–12.
   PubMed Web of Science ®Google Scholar
• HOPE-SIMPSON RE: The nature of herpes zoster; a long term study and a new hypothesis. Proc. R. Soc. Med.(1965) 58:9–20.
   PubMedGoogle Scholar
• KURTZKE JF: Neuroepidemiology. Ann. Nemo]. (1984) 16:265–277.
   PubMed Web of Science ®Google Scholar
• DONOHUE JG, CHOO PW, MANSON JE et al.: The incidence of herpes zoster. Arch. Intern. Med. (1995) 155:1605–1609.
   PubMed Web of Science ®Google Scholar
• HOPE-SIMPSON RE: Studies on shingles: is the virus ordinary chicken pox virus? Lancet (1954) 2:1299–1302.
   Web of Science ®Google Scholar
• WELLER TH, WITTON HM, BELL EJ: The etiologic agents of varicella and herpes zoster: isolation, propagation, and cultural characteristics in vitro. 1. Exp. Med. (1958) 108:843–868.
   PubMed Web of Science ®Google Scholar
• STRAUS SE, REINHOLD W, SMITH HA et al.: Endonuclease analysis of viral DNA from varicella and subsequent zoster infections in the same patient. N. Engl. J. Med. (1984) 311:1362–1364.
   PubMed Web of Science ®Google Scholar
• DWORKIN RH, PERKINS FM, NAGASAKO EM: Prospects for the prevention of postherpetic neuralgia in herpes zoster patients. Clin. J. Pain (2000) 16(Suppl.):S90–S100.
   Google Scholar
• EPSTEIN MA, ACHONG BG, BARR YM: Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet (1964) 15:702–703.
   Web of Science ®Google Scholar
• BURKITT D: A sarcoma involving the jawsin African children. Br. I Stag. (1958) 46:218–224.
   PubMed Web of Science ®Google Scholar
• HENLE G, HENLE W, CLIFFORD P et al.: Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. Natl. Cancerinst. (1969) 43:1147–1157.
   PubMed Web of Science ®Google Scholar
• BABCOCK GJ, DECKER LL, VOLK M et al.: EBV persistence in memory B cells in vivo. Immunity(1998) 9: 395–404.
   Google Scholar
• THORLEY-LAWSON DA, MIYASHITA EM, KHAN G: Epstein-Barr virus and the B cell: that's all it takes. Trends MicrobioL (1996) 4:204–208.
   PubMed Web of Science ®Google Scholar
• NIEDERMAN JC, MILLER G, PEARSON HA et al.: Infectious mononucleosis. Epstein-Barr-virus shedding in saliva and the oropharynx. N Engl. Med. (1976) 294:1355–1359.
   PubMed Web of Science ®Google Scholar
• YAO QY, RICKINSON AB, EPSTEIN MA: A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int. .1. Cancer (1985) 35:35–42.
   Google Scholar
• FLEISHER G, HENLE W, HENLE G et al.: Primary infection with Epstein-Barr virus in infants in the United States: clinical and serologic observations. J. Infect. Dis. (1979) 139:553–558.
   PubMed Web of Science ®Google Scholar
• FLEISHER GR, PASQUARIELLO PS, WARREN WS et al.: Intrafamilial transmission of Epstein-Barr virus infections. Pediatr. (1981) 98:16–19.
   Web of Science ®Google Scholar
• GRATAMA JW, OOSTERVEER MA, KLEIN G et al.: EBNA size polymorphism can be used to trace Epstein-Barr virus spread within families. Vim/. (1990) 64:4703–4708.
   Web of Science ®Google Scholar
• ZHANG LJ, HANFF P, RUTHERFORD C et al.: Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood. J. Infect. Dis. (1995) 171:1002–1006.
   PubMed Web of Science ®Google Scholar
• MASUR H, WHITCUP SM, CART WRIGHT C: Advances in the management of AIDS-related cytomegalovirus retinitis. Ann. Intern. Med. (1996) 125:126–136.
   PubMed Web of Science ®Google Scholar
• WREGHITT TG, TEARE EL, SULE 0 et al.: Cytomegalovirus infection in immunocompetent patients. Clin. Infect. Dis. (2003) 37:1603–1606.
   PubMed Web of Science ®Google Scholar
• SPRUANCE SL, ROWE NH, RABORN GW et al.: Per-oral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: a double-blind, dose-ranging, placebo-controlled, multicenter trial. Infect. Dis. (1999) 179:303–310.
   Web of Science ®Google Scholar
• SPRUANCE SL, STEWART JCB, ROWE NH et al.: Treatment of recurrent herpes simplex labialis with oral acyclovir. J. Infect. Dis. (1990) 161:185–190.
   PubMed Web of Science ®Google Scholar
• SAFRIN S, ASSAYKEEN T, FOLLANSBEE H et al.: Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: prelimary data. J. Infect. Dis. (1990) 161(6):1078–1084.
   PubMed Web of Science ®Google Scholar
• DOCKRELL DH. Human herpesvirus 6: molecular biology and clinical features. J. Med. Microbiol (2003) 52:5–18.
   PubMed Web of Science ®Google Scholar
• IHIRA M, YOSHIKAWA T, OHASHI M et al.: Variation of human herpesvirus 7 shedding in saliva. J. Infect. Dis. (2003) 188:1352–1354.
   PubMed Web of Science ®Google Scholar
• GANDHI M, GREENBLATT RM: Human herpesvirus 8, Kaposi's sarcoma, and associated conditions. Gin. Lab. Med. (2002) 22:883–910.
   Web of Science ®Google Scholar
• SMITH NA, SABIN CA, GOPAL R et al.:Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex. J. Infirt. Dis. (1999) 180:600–606.
   PubMed Web of Science ®Google Scholar
• BOURBOULIA D, WHITBY D, BOSHOFF C et al.: Serologic evidence for mother-to-child transmission of Kaposi sarcoma-associated herpesvirus infection. JA/VIA (1998) 280:31–32.
   Google Scholar
• SPRUANCE SL, STEWART JCB, ROWE NH et al.: Treatment of recurrent herpes simplex labialis with oral acyclovir. J. Infect. Dis. (1990) 161:185–190.
   PubMed Web of Science ®Google Scholar
• SPRUANCE SL, STEWART JCB, ROWE NH et al.: Treatment of recurrent herpes simplex labialis with oral acyclovir. J. Infect. Dis. (1990) 161:185–190.
   PubMed Web of Science ®Google Scholar
• SAFRIN S, ASSAYKEEN T, FOLLANSBEE H et al.: Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: prelimary data. J. Infect. Dis. (1990) 161:1078–1084.
   PubMed Web of Science ®Google Scholar
• MENDEL DB, BARKHIMER DB, CHEN MS: Biochemical basis for increased susceptibility to cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity. Antimicrob. Agents Chemother. (1995) 39:2120–2122.
   PubMed Web of Science ®Google Scholar
• LALEZARI J, SCHACKER T, FEINBERG J: A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J. Infect. Dis. (1997) 176:892–898.
   PubMed Web of Science ®Google Scholar
• WAGSTAFF AJ, HM. B: Foscarnet: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs (1994) 48:199–226.
   PubMed Web of Science ®Google Scholar
• MARTINEZ CM, LUKS-GOLGER DB: Cidofovir use in ACV-resistant herpes infection. Ann. Pharmacother. (1997) 31:1519–1521.
   PubMed Web of Science ®Google Scholar
• SAFRIN S, KEMMERLY S, PLOTKIN B et al.: Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J. Infect. Dis. (1994) 169:193–196.
   PubMed Web of Science ®Google Scholar
• SEVERSON JL, TYRING SK: Relation between herpes simplex viruses and human immunodeficiency virus infections. Arch. Dermatol (1999) 135:1393–1397.
   PubMed Web of Science ®Google Scholar
• STANBERRY LR, SPRUANCE SL, CUNNINGHAM AL et al.: Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl. J. Med. (2002)347:1652–1661.
   PubMed Web of Science ®Google Scholar
• •This paper suggests that a glycoprotein-D vaccine has efficacy in preventing genital herpes in women who are seronegative for both HSV-1 and HSV–2.
   Google Scholar
• RAGOZZINO MW, MELTON LJ, KURLAND LT et al.: Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) (1982) 61:310–316.
   PubMed Web of Science ®Google Scholar
• MILLER AE: Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology (1980) 30:582–587.
   PubMed Web of Science ®Google Scholar
• SCHON F, MAYER ML, KELLY JS: Pathogenesis of post-herpetic neuralgia. Lancet (1987) 2:366–368.
   PubMed Web of Science ®Google Scholar
• SCHMADER K: Management of herpes zoster in elderly patients. Infect. Dis. Pract. (1995) 4:293–299.
   Web of Science ®Google Scholar
• DWORKIN RH, SCHMADER KE: Epidemiology and natural history of herpes zoster and postherpetic neuralgia. In Herpes zoster and postherpetic neuralgia. Watson CP (ed.) Elsevier Press, New York (2001).
   Google Scholar
• BEUTNER KR, FRIEDMAN DJ, FORSZPANIAK C et al.: Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob. Agents Chemother: (1995) 39:1546–1553.
   PubMed Web of Science ®Google Scholar
• GALLAGHER JG, MERIGAN TC: Prolonged herpes-zoster infection associated with immunosuppressive therapy. Ann. Intern. Med. (1979) 91:842–846.
   PubMed Web of Science ®Google Scholar
• WELLER TH: Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl. J. Med. (1983) 309:1362–1368.
   PubMed Web of Science ®Google Scholar
• LOCKSLEY RM, FLOURNOY N, SULLIVAN KM et al.: Infection with varicella-zoster virus after marrow transplantation. J. Infect. Dis. (1985) 152:1172–1181.
   PubMed Web of Science ®Google Scholar
• STOVER BH, BRATCHER DF: Varicella-zoster virus: infection, control, and prevention. Am. J. Infect. Control (1998) 26:369–381.
   PubMed Web of Science ®Google Scholar
• CHRISTIANSEN NP, HAAKE RJ, HURD DD: Early herpes zoster infection in adult patients with Hodgkin's disease undergoing autologous bone marrow transplant. Bone Marrow Transplant (1991) 7:435–437.
   PubMed Web of Science ®Google Scholar
• HAN CS, MILLER W, HAAKE R et al.:Varicella zoster infection after bone marrow transplantation: incidence, risk factors andcomplications. Bone Marrow Transplant (1994) 13:277–283.
   PubMed Web of Science ®Google Scholar
• ROLSTON KV, MANZULLO E, ELTING L et al.: Ambulatory management of varicella-zoster virus infection in immunocompromised cancer patients. Support. Care Cancer (1998) 6:57–62.
   PubMed Web of Science ®Google Scholar
• MEYERS JD, WADE JC, SHEPP DH et al.: Acyclovir treatment of varicella-zoster virus infection in the compromised host. Transplantation (1984) 37:571–574.
   PubMed Web of Science ®Google Scholar
• SHEPP DH, DANDLIKER PS, MEYERS JD: Current therapy of varicella zoster virus infection in immunocompromised patients. A comparison of acyclovir and vidarabine. Am. J. Med. (1988) 85:96–98.
   PubMed Web of Science ®Google Scholar
• HOGLUND M, LJUNGMAN P, WELLER S: Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. Antimicrob. Chemother. (2001) 47:855–861.
   Web of Science ®Google Scholar
• BEAN B, AEPPLI D: Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster. J. Infect. Dis. (1985) 151:362–365.
   PubMed Web of Science ®Google Scholar
• HAEFELI WE, SCHOENENBERGER RA, WEISS P et al.: Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose. Am. J. Med. (1993) 94:212–215.
   PubMed Web of Science ®Google Scholar
• PAGANO JS, SIXBEY JVV, LIN JC: Acyclovir and Epstein-Barr virus infection. Antimicrob. Chemother. (1983) 12:113–121.
   Web of Science ®Google Scholar
• ANDERSSON J, BRITTON S, ERNBERG I et al.: Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study. J. Infect. Dis. (1986) 153:283–290.
   PubMed Web of Science ®Google Scholar
• CALLAN MF, TAN L, ANNELS N et al.:Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. (1998) 187:1395–1402.
   PubMed Web of Science ®Google Scholar
• KUZUSHIMA K, YAMAMOTO M, KIMURA H et al.: Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection. Clin. Exp. Immunol. (1996) 103:192–198.
   PubMed Web of Science ®Google Scholar
• OKAMURA T, HATSUKAWA Y, ARM H et al.: Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation. Lancet (2000) 356:223–224.
   PubMed Web of Science ®Google Scholar
• MEYERS JD, FLOURNOY N, EDT: Risk factors for cytomegalovirus infection after human marrow transplantation. Infect. Dis. (1986) 153:478–488.
   Web of Science ®Google Scholar
• PATEL R, SNYDMAN DR, RUBIN RH et al.: Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation (1996) 61:1279–1289.
   PubMed Web of Science ®Google Scholar
• PESCOVITZ MD: Formulary considerations for drugs used to prevent cytomegalovirus disease. Am. Health Syst. Pharm. (2003) 60:S17–S21.
   PubMed Web of Science ®Google Scholar
• MEIJER E, BOLAND GJ, VERDONCK LF: Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin. Microbiol. Rev (2003) 16:647–657.
   PubMed Web of Science ®Google Scholar
• GALLANT JE, MOORE RD, RICHMAN DD et al.: Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficienty virus treated with zidovudine. I Infect. Dis. (1992) 166:1223–1227.
   Web of Science ®Google Scholar
• SPECTOR SA, MCKINLEY GE LALEZARI JP et al.: Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl. I Med. (1996) 334:1491–1497.
   PubMed Web of Science ®Google Scholar
• MARTIN DF, PARKS DJ, MELLOW SD et al.: A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis. N Engl. I Med. (2002) 346:1119–1126.
   PubMed Web of Science ®Google Scholar
• PAYA C, HUMAR A, DOMINGUEZ E et al.: Efficacy and safety of valganciclovir versus oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant patients. Am. I Transplant. (2004) 4:611–620.
   Web of Science ®Google Scholar
• Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarent or ganciclovir for cytomegalovirus retinitis. N Engl.' Med. (1992) 326:213–220.
   PubMed Web of Science ®Google Scholar
• DECLERCQ E: Antiviral drugs in current clinical use. Clin. Virol. (2004) 30:115–133.
   PubMed Web of Science ®Google Scholar
• BURNS WH, SANFORD GR: Susceptibility of human herpesvirus 6 to antivirals in vitro. I Infect. Dis. (1990) 162:634–637.
   PubMed Web of Science ®Google Scholar
• JONES JL, HANSON DL, DWORKIN MS et al.: Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J. Acquit: Immune Defic. Syndr: (2000) 24:270–274.
   PubMed Web of Science ®Google Scholar
• DEZUBE BJ: New therapies for the treatment of AIDS-related Kaposi sarcoma. Can: Opin. amyl. (2000) 12:445–449.
   PubMed Web of Science ®Google Scholar
• DE WIT R, SCHATTENKERK JK, BOUCHER CA et al.: Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet (1988) 2:1214–1217.
   PubMed Web of Science ®Google Scholar
• MILES SA, DEZUBE BJ, LEE JY et al.: Antitumor activity of oral 9-cisretinoic acid in HIV-associated Kaposi's sarcoma. AIDS (2002) 16:421–429.
   PubMed Web of Science ®Google Scholar
• SLADE HB, OWENS ML, TOMAI MA et al.: Imiquimod 5% cream (AldaraTM). Expert Opin. Investig. Drugs (1998) 7:437–450.
   PubMedGoogle Scholar
• HARRISON CJ, MILLER RL, BERNSTEIN DI: Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob. Agents Chemother. (1994) 38:2059–2064.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN B, HENGGE UR: Recurrent urogenital herpes simplex: successful treatment with imiquimod? Sex. Transm. Infect. (1999) 75:132–133.
   PubMed Web of Science ®Google Scholar
• GILBERT J, DREHS MM, WEINBERG JM: Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2 infection. Arch. Dermatol. (2001) 137:1015–1017.
   PubMed Web of Science ®Google Scholar
• SCHACKER TW, CONANT M, THOMING C et al.: Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a Phase II, randomized, double-blind, placebo-controlled study. Antimicrob. Agents Chemother. (2002) 46:3243–3248.
   PubMed Web of Science ®Google Scholar
• CRUTE JJ, GRYGON CA, HARGRAVE KD et al.: Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med. (2002) 8:386–391.
   PubMed Web of Science ®Google Scholar
• ••One of the first two reports on the efficacyhelicase primase inhibitors for HSV-1 and HSV-2 in the animal model.
   Google Scholar
• KLEYMANN G, FISCHER R, BETZ UA et al.: New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat. Med. (2002) 8:392-398.One of the first two reports on the efficacy helicase primase inhibitors for HSV-1 and HSV-2 in the animal model.
   PubMed Web of Science ®Google Scholar
• SPRUANCE SL, REA TL, THOMING C et al.: Penciclovir cream for the treatment of herpes simplex labialis: a randomized, multicenter, double-blind, placebo-controlled trial. JAMA (1997) 277:1374–1379.
   PubMed Web of Science ®Google Scholar
• SPRUANCE SL, JONES TM, BLATTER M et al.: High-dose, short-duration, early valacyclovir therapy for the episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob. Agents Chemother: (2003) 47:1072–1080.
   PubMed Web of Science ®Google Scholar
• BROWN TJ, YEN-MOORE A, TYRING SK: An overview of sexually transmitted diseases, Part I. .1 Am. Acad. Dermatol. (1999) 41:511–529.
   PubMed Web of Science ®Google Scholar
• BROWN TJ, VANDERSTRATEN M, TYRING SK: Antiviral agents. Dermatol. Clin. (2001) 19:23–24.
   PubMed Web of Science ®Google Scholar
• LAZARUS HM, BELANGER R, CANDONI A et al.: Intraveous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multi-center, acyclovir-controlled trial. Antimicrob. Agents Chemother. (1999) 43:1192–1197.
   PubMed Web of Science ®Google Scholar
• ISRAEL BE KENNEY SC: Virally targeted therapies for EBV-associated malignancies. Oncogene (2003) 22:5122–5130.
   PubMed Web of Science ®Google Scholar
• GU S-Y, HUANG T-M, RUAN L et al.: First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev. Biol. Stand (1995) 84:171-177. 93.KLEMOLA E, VON ESSEN R, HENLE G et al.: Infectious mononucleosis-like disease with negative heterophil agglutination testL clinical features in realtion to Epstein-Barr virus and cytomegalovirus antibodies.Infect. Dis. (1970) 121:608–614.
   Google Scholar
• ERTL PF, POWELL KL: Physical and functional interation of human cytomegalovirus DNA polymerase and its accessory protein (ICP36) expressed in insect cells. I Virol. (1992) 66:4126–4133.
   PubMed Web of Science ®Google Scholar
• EINSELE H, ROOSNEK E, RUFER N et al.: Infusion of cytomegalovirs (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood(2002) 99: 3916–3922.
   Google Scholar
• EINSELE H, HAMPRECHT K: Immunotherapy of cytomegalovirus infection after stem-cell transplantation: a new option? Lancet (2003) 362:1343–1344.
   PubMed Web of Science ®Google Scholar
• DE BOLLE L, ANDREI G, SNOECK R et al.: Potent, selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nuceloside compound CMV423. Biochem. Pharmacol (2004) 67:325–326.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, SCHOLS D, DE CLERQ E: Selective activity of various antiviral compunds against HHV-7 infection. Antiviral Res. (1999) 43:23–35.
   PubMed Web of Science ®Google Scholar
• SGADARI C, MONINI P, BARILLARI G et al.: Use of HIV protease inhibitors to block Kaposi's sarcoma and tumor growth. Lancet °flea (2003) 4:537–547.
   PubMed Web of Science ®Google Scholar
• HENGGE UR, RUZICKA T, TYRING SK et al.: Update on Kaposi's sarcoma and other HHV-8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect. Dis. (2002) 2:281–292.
   PubMed Web of Science ®Google Scholar
• EVANS TY,TYRING SK: Advances in antiviral therapy in dermatology. Dermatol Clin. (1998) 16:409–419.
   PubMed Web of Science ®Google Scholar
• •Good overview of antiviral therapy.
   Google Scholar
• HUFF JC,BEAN B,BALFOUR HH et al.: Therapy of herpes zoster with oral acyclovir. Am. J. Med. Sci (1988) 85 (Suppl. 2A):84–89.
   Google Scholar
• WOOD MJ, OGAN PH, MCKENDRICK MW et al.: Efficacy of oral acyclovir treatment of acute herpes zoster. Am. Med. (1988)85 (Suppl. 2A):79–83.
   PubMed Web of Science ®Google Scholar
• WOOD MJ, KAY R, DWORKIN RH et al.: Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin. Infect. Dis. (1996) 22:341–347.
   PubMed Web of Science ®Google Scholar
• EVANS TY, VANDERSTRATEN MR, CARRASCO DA et al.: Systemic antiviral agents. In Comprehensive Dermatologic Drug Therapy Wolverton SE (ed.) W.B. Saunders, Philadelphia (2001):85–106.
   Google Scholar
• BURNETTE TC, DEMIRANDO P: Metabolic disposition of the acyclovir prodrug valacyclovir in the rat. Drug Metab. Dispos. (1994) 22:60–64.
   PubMed Web of Science ®Google Scholar
• DEMIRANDO P, BURNETTE TC: Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. Drug Metab. Dispos. (1994) 22:55–59.
   PubMed Web of Science ®Google Scholar
• FIFE KH, BARBARASH RA, RUDOLPH T et al.: Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. Sex. Transm. Dis. (1997) 24:481–486.
   PubMed Web of Science ®Google Scholar
• SPRUANCE SL, TYRING SK, DEGREGORIO B et al.: A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch. Intern. Med. (1996) 156:1729–1735.
   PubMed Web of Science ®Google Scholar
• REITANO M, TYRING S, LANG W et al.: Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. Infect. Dis. (1998) 178:603–610.
   Web of Science ®Google Scholar
• CONANT MA, SCHACKER TW, MURPHY RL et al.: Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Lit. I STD AIDS (2002) 13:12–21.
   PubMed Web of Science ®Google Scholar
• COREY L, WALD A, PATEL R et al.: Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl. Med. (2004) 350:11–20.
   PubMed Web of Science ®Google Scholar
• •This study showed that chronic suppressive therapy with valacyclovir can prevent the transmission of genital herpes in discordant couples.
   Google Scholar
• BEUTNER KR: Antivirals in the treatment of pain. Geriatr. Dermatol (1994) 6 (Supp1.2):23A–28A.
   Google Scholar
• MALOUF MA,CHHAJED PN,HOPKINS P et al.: Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. I Heart Lung Transplant. (2002) 21:547–554.
   PubMed Web of Science ®Google Scholar
• LOWANCE D, NEUMAYER HH, LEGENDRE CM et at Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl. Med. (1999) 340:1462–1470.
   PubMed Web of Science ®Google Scholar
• VUSIRIKALA M, WOLFF SN, STEIN RS et al.: Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Bone Marrow Transplant. (2001) 28:265–270.
   PubMed Web of Science ®Google Scholar
• LJUNGMAN P, DELACAMARA R, MILPIED N et al.: Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood (2002) 99:3050–3056.
   PubMed Web of Science ®Google Scholar
• EGAN JJ, CARROLL KB, YONAN N et al.: Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial. J. Heart Lung Transplant. (2002) 21:460–466.
   PubMed Web of Science ®Google Scholar
• TYRING SK, BARBARASH RA, NAHLIK JE et al.: Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia, a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1995) 123:89–96.
   PubMed Web of Science ®Google Scholar
• HUSE DM, SCHAINBAUM S, AJ K: Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia. Am. I Health Syst. Pharm. (1997) 54:1180–1184.
   PubMed Web of Science ®Google Scholar
• TYRING SK, ENGST R, CORRIVEAU C et al.: Famciclovir for ophthalmic zoster: a randomized acycolvir controlled study. &I. Ophthalmol (2001) 85: 576–581.
   Google Scholar
• TYRING SK, BEUTNER KR, TUCKER BA et al.: Antiviral therapy for herpes zoster. Arch. Fam. Med. (2000) 9:863–869.
   PubMedGoogle Scholar
• BOYD MR, SAFRIN S, ER K: Penciclovir: a review of the spectrum of activity, selectivity, and cross resistance pattern. Antivir. Chem. Chemother. (1993) 4:3–11.
   Web of Science ®Google Scholar
• FIELD AK, DAVIES ME, DEWITT C et al.: 9-([2-hydroxy-1- (hydroxymethy9 ethoxy] methy9 guanine: a selective inhibitor of herpes group virus replication. Proc. Natl. Acad. Sci. USA (1983) 80:4139–4143.
   PubMed Web of Science ®Google Scholar
• MANISCHEWITZ JF, QUINNAN GV J, LANE HC et al.: Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. (1990) 34:373–375.
   Web of Science ®Google Scholar
• GISH RG, LAU JY, BROOKS L et al.: Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology (1996) 23:1–7.
   PubMed Web of Science ®Google Scholar
• MEDINA DJ, HSIUNG GD, JW M: Ganciclovir antagonizes the anti-human immunodeficiency virus Type 1 activity of zidovudine and didanosine in vitro. Antimicrob. Agents Chemother. (1992) 36:1127–1130.
   PubMed Web of Science ®Google Scholar
• LAVELLE J, FOLLANSBEE S, TRAPNELL CB et al.: Effect of food on the relative bioavailability of oral ganciclovir. Clin. Pharmacol (1996) 36:238–241.
   Google Scholar
• FLETCHER C, SAWCHUK R, CHINNOCK B et al.: Human pharmacolkinetics of the antiviral drug DHPG. Clin. Pharmacol Ther: (1986) 40:281–286.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS: Treatment of serious cytomegalovirus infections with 941,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl. I Med. (1986) 314:801–805.
   PubMed Web of Science ®Google Scholar
• HOLLAND GN, SIDIKARO Y, KREIGER AE et al.: Treatment of cytomegalovirus retinopathy with ganciclovir. Ophthalmology (1987) 94:815–823.
   PubMed Web of Science ®Google Scholar
• LASKIN OL, CEDERBERG DM, MILLS J et al.: Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am. J. Med. (1987) 83:201–207.
   PubMed Web of Science ®Google Scholar
• SOMERVILLE KT: Cost advantages of oral drug therapy for managing cytomegalovirus disease. Am. .1. Health Syst. Pharm. (2003) 60:S9–S12.
   PubMed Web of Science ®Google Scholar
• DIETERICH DT, KOTLER DP, BUSCH DF et al.: Ganciclovir treatment of cytomegalovirus colitis in AIDS: a randomized, double-blind, placebo-controlled multicenter study. Infect. Dis. (1993) 167:278–282.
   Web of Science ®Google Scholar
• SCHMIDT GM, HORAK DA, NILAND JC et al.: A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl. I Med. (1991) 324:1005–1011.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS: Valganciclovit: new preparation. CMV retinitis: a simpler, oral treatment. Prescribe Int. (2003) 12:133–135.
   PubMedGoogle Scholar
• HARDY WD: Combined ganciclovir and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. I Acquir: Immune Defic. Syndr. (1991) 4:S22–S28.
   PubMed Web of Science ®Google Scholar
• FAULDS D, HEEL RC: Ganciclovir: a review of its antiviral activity, pharmacolkinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs (1990) 39:597–638.
   PubMed Web of Science ®Google Scholar
• JUNG D, DORR A: Single-dose pharmacolkinetics of valganciclovir in HIV-and CMV-seropositive subjects. Clin. Pharmacol (1999) 39:800–804.
   Google Scholar
• LALEZARI JP, STAGG RJ, JAFFE HS et al.: A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC). Adv. Exp. Med. Biol. (1996) 394:105–115.
   PubMedGoogle Scholar
• SAFRIN S, CHERRINGTON J, HS J: Clinical uses of cidofovir. Rev Med. Virol (1997) 7:145–156.
   PubMed Web of Science ®Google Scholar
• DECLERCQ E: Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbial. Rev (2003) 16:569–596.
   PubMed Web of Science ®Google Scholar
• SNOECK R, DECLERCQ E: Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients. Carr. Opin. Investig. Drugs (2002) 3:1561–1566.
   PubMedGoogle Scholar
• ANDREI G, SNOECK R, VANDEPUTTE M et al.: Activities of various compounds against murine and primate polyomaviruses. Antimicrob. Agents Chemother. (1997) 41:587–593.
   PubMed Web of Science ®Google Scholar
• CHERRINGTON JM, MINER R, HITCHCOCK MJ et al.: Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various regiments of drug. Infect. Dis. (1996) 173:987–992.
   Web of Science ®Google Scholar
• NEAU D, RENAUD-ROUGIER MB, VIALLARD JE et al.: Intravenous cidofovir-induced iritis. Clin. Infect. Dis. (1999) 28:156–157.
   PubMed Web of Science ®Google Scholar
• DETRICK B, NAGINENI CN, GRILLONE LR et al.: Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides. Invest. Ophthalmol Vis. Sci. (2001) 42:163–169.
   PubMed Web of Science ®Google Scholar
• ANDERSON KP, FOX MC, BROWN-DRIVER V et al.: Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob. Agents Chemother: (1996) 40:2004–2011.
   PubMed Web of Science ®Google Scholar
• VITRAVENE STUDY GROUP: A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am. Opthalmol (2002) 133:484–498.
   PubMed Web of Science ®Google Scholar
• VITRAVENE STUDY GROUP: Safety of intraveous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am. J. Opthalmol (2002) 133:484–498.
   PubMed Web of Science ®Google Scholar
• KEDES DH, GANEM D: Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. I Clin. Invest. (1997) 99:2082–2986.
   PubMed Web of Science ®Google Scholar
• SELLESETH DW, TALARICO CL, MILLER T et al.: Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. Antimicrob. Agents Chemother. (2003) 47:1468–1471.
   PubMed Web of Science ®Google Scholar
• ERIKSSON BF, SCHINAZI RF: Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phsophonoformate (foscarnet) against human immunodeficiency virus Type 1 and cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. (1989) 33:663–669.
   PubMed Web of Science ®Google Scholar
• JABS DA, DUNN JP, ENGER C et al.: Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Arch. Ophthalmol (1996) 114:809–814.
   PubMed Web of Science ®Google Scholar
• PALESTINE AG, POLIS MA, DE SMET MD et al.: A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann. Intern. Med. (1991) 115:665–673.
   PubMed Web of Science ®Google Scholar
• JACOBSON MA, DREW WL, FEINBERG J et al.: Foscarnet therapy for ganciclovir-resistantg cytomegalovirus retinitis in patients with AIDS. I Infect. Dis. (1991) 163:1348–1351.
   Web of Science ®Google Scholar
• ANONYMOUS: Combination foscarnet and ganciclovir therapy versus monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: the Cytomegalovirus Retreatment Trial. Arch. Ophthalmol (1996) 114:23–33.
   PubMed Web of Science ®Google Scholar
• NOORMOHAMED FH, YOULE MS, HIGGS CJ et al.: Pharmacolkinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients. Antimicrob. Agents Chemother: (1998) 42:293–297.
   PubMed Web of Science ®Google Scholar
• HENGGE UR, BROCKMEYER NH, MALESSA R et al.: Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis. Antimicrob. Agents Chemother: (1993) 37:1010–1014.
   PubMed Web of Science ®Google Scholar
• AREVALO JF, GONZALEZ C, CAPPARELLI EV et al.: Intravitreous and plasma concentrations of ganciclovir and foscarnet after intraveous therapy in patients with AIDS and cytomegalovirus retinitis. .1. Infect. Dis. (1995) 172:951–956.
   Google Scholar
• DERAY G,MARTINEZ F,KATLAMA C et al.: Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am. J. Nephrol (1989) 9:316–321.
   PubMed Web of Science ®Google Scholar
• JAYAWEERA DT: Minimising the dosage-limiting toxicities of foscarnet induction therapy. Drug Saf (1997) 16:258–266.
   PubMed Web of Science ®Google Scholar
• JACOBSON MA,GAMBERTOGLIO AG,AWEEKA FT et al.: Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J. Clin. Endocrinol (1991) 72:1130–1135.
   PubMed Web of Science ®Google Scholar
• HEMMI H, KAISHO T, TAKEUCHI 0 et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol (2002) 3:196–200.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN DI, HARRISON CJ, TOMAI MA et al.: Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. .1. Infect. Dis. (2001) 183:844–849.
   Google Scholar
• SPRUANCE S, TYRING S, SMITH M et al.: Application of a topically applied immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. Infect. Dis. (2001) 84:196–200.
   Web of Science ®Google Scholar
• ••This paper highlights the first successful use of resiquimod for recurrent genital herpes.
   Google Scholar
• BETZ UA, FISCHER R, KLEYMANN G et al.: Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob. Agents Chemother: (2002) 46:1766–1772.
   PubMed Web of Science ®Google Scholar
• KLEYMANN G: New antivirals drugs that target herpesvirus helicase primase enzymes. Herpes (2003) 10:46–52.
   PubMedGoogle Scholar
• DUAN J, LIUZZI M, PARIS W et al.: Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus Type 1. Antimicrob. Agents Chemother. (2003) 47:1798–1804.
   PubMed Web of Science ®Google Scholar
• REYNOLDS SJ, RISBUD AR, SHEPHERD M et al.: Recent herpes simplex virus Type 2 infection and the risk of human immunodeficiency virus Type 1 acquisition in India. Infect. Dis. (2003) 187:1513–1521.
   Web of Science ®Google Scholar
• ROSKROW MA, SUZUKI N, GAN Y-J et al.: Epstein-Bar virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood (1998) 91:2925–2934.
   PubMed Web of Science ®Google Scholar
• WANG QJ, JENKINS EJ, JACOBSON LP et al.: Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic proteins. Blood (2001) 97:2366–2373.
   PubMed Web of Science ®Google Scholar